Alvotech and Cipla Receive Marketing Authorization for AVT02 (biosimilar, adalimumab) in Australia
Shots:
- The company reported that Cipla has received marketing authorization for Alvotech's AVT02, a high-concentration low-volume biosimilar to Humira (adalimumab) by the Therapeutic Goods Administration of Australia
- Alvotech’s biosimilar will be available as a 40mg/0.4mL and 80mg/0.8mL solution in a pre-filled syringe and 40mg/0.4mL solution in a pre-filled pen
- AVT02 is a mAb that inhibits tumor necrosis factor & will be marketed as Ciptunec and Ardalicip. The biosimilar has been approved in the EU, Norway, Iceland, Lichtenstein, the UK, and Switzerland as Hukyndra; and in Canada and Saudi Arabia as Simlandi & is currently under review in multiple countries, incl. US
Ref: Globenewswire | Image: Alvotech
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
